Form 4: Director Steven Gannon Executes Equity Transactions at XENE

Director Steven Gannon acquired common shares through RSU vesting and received new equity grants in Xenon Pharmaceuticals.

Summary

• Director Steven Gannon acquired 2,645 common shares on June 1, 2026, upon the vesting of restricted share units (RSUs).
• The company withheld 1,416 shares to satisfy tax obligations related to the RSU settlement, resulting in a net increase of 1,229 shares.
• The reporting person was granted 10,507 share options and 1,593 new RSUs on June 3, 2026.
• Following these transactions, the director holds 11,870 common shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity management.

Positives

• Director maintains a direct equity stake in the company, aligning interests with shareholders.
• Equity grants indicate ongoing commitment and retention of board leadership.

Negatives

• The transaction involved a net settlement where shares were withheld for tax purposes, which is standard but reduces the total potential share count increase.

Risks

• Future value of equity grants is subject to market volatility and the company's share price performance.

Future Outlook

The newly granted options and RSUs are scheduled to vest 100% on the earlier of June 1, 2027, or the day before the 2027 annual meeting of shareholders.

Management Comments

• Transactions were executed in accordance with standard equity compensation plans.

Industry Context

StockSavvy.ai notes that routine equity vesting and annual grants for directors are standard corporate governance practices in the biotechnology sector, serving to align board incentives with long-term shareholder value.

Comparison to Industry Standards

• The use of net settlement for tax obligations is a standard practice among mid-cap and large-cap pharmaceutical companies.
• The vesting schedule tied to annual shareholder meetings is consistent with typical board compensation structures in the industry.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as these are standard compensatory equity grants.

Next Steps

• Vesting of new RSU and option grants on or before June 1, 2027.

Key Dates

Keywords

Xenon Pharmaceuticals, XENE, Form 4, Insider Trading, Equity Compensation, Director Ownership